Jazz Pharmaceuticals' Modeyso™ Receives Key Endorsement in Cancer Treatment

On September 9, 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced a significant milestone for its cancer treatment, Modeyso™ (dordaviprone). The National Comprehensive Cancer Network® (NCCN®) has included Modeyso in its Clinical Practice Guidelines in Oncology as a category 2A single-agent treatment for patients—both pediatric and adult—with recurrent or progressive diffuse high-grade glioma characterized by the H3 K27M mutation. This endorsement underscores the urgent need for effective therapies in a patient population facing a grim prognosis.

Kelvin Tan, MB BCh, MRCPCH, Chief Medical Affairs Officer at Jazz Pharmaceuticals, expressed the importance of this inclusion, emphasizing the dire circumstances that patients encounter when diagnosed with H3 K27M-mutant diffuse midline glioma. "The rapid addition of Modeyso to the NCCN Guidelines reflects the urgency of the unmet need that patients are faced with when diagnosed with this devastating and aggressive brain tumor," he stated. This first-line recommendation marks a crucial shift in the treatment landscape for patients and their families.

Modeyso received accelerated approval from the U.S. Food and Drug Administration (FDA) on August 6, 2025. This approval was based on an integrated efficacy analysis of 50 patients with recurrent H3 K27M-mutant diffuse midline glioma. The overall response rate (ORR) observed was 22%, as assessed by blinded independent central review (BICR) using the Response Assessment in Neuro-Oncology (RANO) 2.0 criteria. Among those who responded to the treatment, the median duration of response was reported to be 10.3 months, with a substantial percentage maintaining their response for at least six months.

The safety data for Modeyso were derived from a pooled analysis of 376 patients across four open-label clinical studies. Serious adverse reactions were noted in 33% of these patients, with hydrocephalus, vomiting, headache, seizure, and muscular weakness being the most frequently reported serious adverse reactions. The most common adverse reactions included fatigue, headache, vomiting, nausea, and musculoskeletal pain. Given these findings, ongoing monitoring and reporting of adverse events will be crucial as the treatment becomes more widely used.

H3 K27M-mutant diffuse midline glioma is a rare and aggressive brain tumor that predominantly affects the midline structures of the brain and spinal cord. Characterized by a mutation that disrupts epigenetic regulation, this type of glioma is often diagnosed in children and young adults. The prognosis is notably poor, with median survival rates hovering around one year from diagnosis and dropping below six months following disease progression.

Modeyso is an orally administered small molecule that acts as a protease activator, specifically targeting mitochondrial caseinolytic protease P (ClpP). The drug has shown potential in restoring histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma, thereby influencing tumor growth and response to treatment. It is administered once weekly, providing a convenient treatment option for patients.

While the accelerated approval of Modeyso offers hope for patients and families affected by this aggressive form of glioma, continued approval is contingent upon ongoing clinical trials, notably the Phase 3 ACTION trial. This study aims to further evaluate the safety and clinical benefits of Modeyso in newly diagnosed patients following radiotherapy.

Jazz Pharmaceuticals' inclusion of Modeyso in the NCCN Guidelines is a landmark moment in the fight against H3 K27M-mutant diffuse midline glioma. The approval represents a critical step towards addressing the significant unmet medical needs in this patient population, providing hope for improved outcomes in a challenging and often devastating diagnosis. As the ongoing trials progress, the medical community and patients alike will be closely monitoring the results and further developments surrounding this promising treatment.